MEK inhibition modulates cytokine response to mediate therapeutic efficacy in lung cancer

Activating mutations in BRAF, a key mediator of RAS signaling, are present in ~50% of melanoma patients. Pharmacological inhibition of BRAF or the downstream MAP kinase MEK are highly effective in treating BRAF-mutant melanoma. In contrast, RAS pathway inhibitors have been less effective in treating...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Res
Main Authors: Xie, Mengyu, Zheng, Hong, Madan-Lala, Ranjna, Dai, Wenjie, Gimbrone, Nicholas T., Chen, Zhihua, Kinose, Fumi, Blackstone, Sarah A., Smalley, Keiran S. M., Cress, W. Douglas, Haura, Eric B., Rix, Uwe, Beg, Amer A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6881545/
https://ncbi.nlm.nih.gov/pubmed/31362929
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-19-0698
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados